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Abstract- Familial Mediterranean fever (FMF) is a relatively rare disorder, characterized by recurrent 
self-limited attacks of fever and polyserositis. Diagnosis is made by clinical features, gene identification 
on chromosome 16 and clinical response to specific treatment. Different types of vasculitis have been 
reported in FMF. Henoch-Schönlein purpura (HSP) is one of them, usually with a benign clinical 
course. Repeated attacks of HSP have been rarely reported in FMF. This is the report of a 7-year-old 
girl who presented initially with recurrent fever and abdominal pain. After the primary diagnosis of 
FMF and appropriate treatment, she experienced two documented repeated attacks of HSP with severe 
renal involvement (crescentic glomerulonephritis) and protracted abdominal pain in the second one. 
Glomerulonephritis was controlled by methyl-prednisolone pulse therapy plus oral corticosteroid and 
azathioprine, but abdominal pain was resistant to steroids and revealed completely by intravenous 
immunoglobulin (IVIg) administration. In conclusion, it is suggested to consider the recurrence of HSP 
in cases with FMF to prevent irreversible renal complications. IVIg seems to be a good choice for the 
management of intractable abdominal pain of HSP. 
© 2008 Tehran University of Medical Sciences. All rights reserved. 
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Familial Mediterranean fever (FMF) or paroxysmal 
polyserositis is an inherited disorder characterized by 
recurrent attacks of fever, abdominal pain, 
arthritis/arthralgia (1) and skin eruptions ranging 
from typical erysipelas-like erythema to non-specific 
purpuric rash or angioneurotic edema (2). It is more 
prevalent among Eastern Mediterranean populations,  
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especially non-Ashkenazi Jews, Armenians, Turks 
and Arabs (1, 3). Responsible gene (MEFV) has 
been identified on chromosome 16, with more than 
50 different point mutations (4, 5).  
Various types of vasculitis such as polyarteritis 
nodosa (0.9%), Henoch-Schönlein purpura (HSP) 
(5%), febrile myalgia (6) and Behçet disease may be 
associated with FMF (7). It has been claimed that 
gene mutation and/or environmental factors are 
responsible for impaired control of inflammatory 
response and vasculitis in FMF (6, 8). HSP may be 
presented with its complete and benign clinical 
course in FMF, but recurrent episodes have been 
rarely reported.  
In this article, we report a case of FMF with 
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The patient was a 7-year-old girl with 18 months 
history of recurrent fever, abdominal and articular 
pain and occasional skin rash. Screening for FMF 
disease by cloning and gene identification on 
chromosome 16 was positive and treatment 
commenced effectively with colchicine.  
A few months later, she experienced abdominal 
pain, joint swelling and petechial lesions on her legs 
and buttocks. Leukocytoclastic vasculitis was 
reported in skin biopsy in favor of HSP. She was 
treated conservatively with full recovery. 
During the present admission, about 7 months 
later, she again had clinical manifestations of HSP. 
Her blood pressure was 110/70 mmHg. Laboratory 
exams revealed mild normochromic normocytic 
anemia, normal renal function, elevated ESR, 
negative CRP, glomerular hematuria with RBC casts 
and mild proteinuria. All of the serologic tests were 
negative. IgA level was high and serum complement 
level was normal. Class 3b crescentic 
glomerulonephritis of HSP with deposition of C3 
and IgA in the mesangial area was documented in 
kidney biopsy specimen (Fig. 1). Therefore, it was 
the second documented episode of HSP in this case 
with FMF. The patient was treated with steroid pulse 
therapy along with oral prednisolone, azathioprine 
and colchicine. Majority of symptoms improved, 
except for protracted abdominal pain, which was 
completely controlled by intravenous immunoglobulin 
(IVIg) administration (200 mg/kg for 5 days).  
We obtained informed consent to publish details 
of the patient’s history. 
 
 
Fig. 1. Renal biopsy of the patient showing class 3b 
crescentic glomerulonephritis of Henoch-Schönlein purpura. 
(Hematoxylin-eosine staining, × 400). 
DISCUSSION 
 
Our patient was a case of periodic fever, abdominal 
pain and occasional skin eruptions. There are a few 
syndromes characterized by periodic fever (9, 10). 
One of them is hyperimmune globulin D fever with 
recurrent short episodes of fever, cervical 
lymphadenopathy, abdominal pain, arthralgia, skin 
rash, elevated acute phase reactants and IgD level 
(11). Tumor necrosis factor (TNF) associated 
syndrome is another disorder with intermittent fever, 
abdominal pain, myalgia, occasional rash, 
conjunctivitis, and unilateral periorbital edema, with 
increased level of acute phase reactants and a low 
serum level of TNF receptor. Another disease is 
periodic fever with aphthous stomatitis, pharyngitis, 
lymph adenitis and arthralgia, with spontaneous 
improvement within 4-8 years (9). None of the 
above diagnoses was compatible to our patient’s.  
Another syndrome characterized by periodic 
fever is FMF, which presents with fever and one or 
more symptoms of abdominal pain, arthralgia or 
arthritis and serosal involvement. Accumulation of 
C5a leads to acute attack in this disease. Diagnosis is 
based on clinical manifestation, genetic analysis and 
response to colchicine treatment, as our patient. Its 
specific gene (MEFV) has been localized to the short 
arm of chromosome 16, which mediates organ 
inflammation (4).  
Renal involvement is usually in the form of AA 
amyloidosis in FMF (8). They are also at greater risk 
for developing nephrotic syndrome due to IgA and 
IgM nephropathy, mesangial proliferative 
glomerulonephritis (12) and renal complications of 
HSP (13).  
HSP is a rare manifestation in FMF. It is 
considered to be an IgA mediated vasculitis with 
leukocytoclastic angitis. Clinical feature consist of 
arthralgia, abdominal pain, skin eruption and renal 
involvement. Each of these symptoms could be 
severe enough to mandate a serious treatment (14). 
In a study by Gershoni-Baruch et al., occult FMF 
was identified in cases with HSP and they 
recommended closed monitoring of renal 
complications (15).  
HSP may recur during a subsequent reactive 
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review, repeated attacks of HSP have been rarely 
reported in FMF. In this case report, our patient 
experienced at least 2 documented episodes of HSP. 
She had also a severe and steroid resistant abdominal 
pain during the course of HSP, which was managed 
completely by IVIg administration. IVIg have been 
reported to be efficient in recurrent and intractable 
gastrointestinal symptoms of HSP (16, 17). Its 
mechanism of action is complex, including 
modulating the Fc receptors, interference with 
complement and cytokine network, and effects on 
activation and differentiation of T and B-cells (18). 
It has also a renoprotective effect (19) by reducing 
proteinuria, hematuria, leukocyturia, the histological 
index of renal biopsy and serum level of IgA and 
beta 2-microglobulin (20).  
In conclusion, it is suggested to consider the 
recurrence of HSP in cases with FMF to prevent 
irreversible renal complications. IVIg seems to be a 
good choice in the management of intractable 




1. Bakkaloglu A. Familial Mediterranean fever. Pediatr 
Nephrol. 2003 Sep;18(9):853-859.  
2. Majeed HA, Quabazard Z, Hijazi Z, Farwana S, 
Harshani F. The cutaneous manifestations in children 
with familial Mediterranean fever (recurrent hereditary 
polyserositis). A six-year study. Q J Med. 1990 Jun; 
75(278):607-616. 
3. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, 
Yalcinkaya F, Tutar E, Ozen S, Topaloglu R, Yilmaz 
E, Arici M, Bakkaloglu A, Besbas N, Akpolat T, Dinc 
A, Erken E; Turkish FMF Study Group. Familial 
Mediterranean fever (FMF) in Turkey: results of a 
nationwide multicenter study. Medicine (Baltimore). 
2005 Jan; 84(1):1-11. 
4. Kutlay S, Sengul S, Keven K, Erturk S, Erbay B. Two 
sisters with familial Mediterranean fever: lack of 
correlation between genotype and phenotype? J 
Nephrol. 2006 Jan-Feb;19(1):104-107. 
5. Medlej-Hashim M, Serre JL, Corbani S, Saab O, Jalkh 
N, Delague V, Chouery E, Salem N, Loiselet J, Lefranc 
G, Mégarbané A. Familial Mediterranean fever (FMF) 
in Lebanon and Jordan: a population genetics study and 
report of three novel mutations. Eur J Med Genet. 2005 
Oct-Dec;48(4):412-420.  
6. Tekin M, Yalçinkaya F, Tümer N, Akar N, Misirlioğlu 
M, Cakar N. Clinical, laboratory and molecular 
characteristics of children with Familial Mediterranean 
Fever-associated vasculitis. Acta Paediatr. 2000 Feb; 
89(2):177-182. 
7. Cattan D. MEFV mutation carriers and diseases other 
than familial Mediterranean fever: proved and non-
proved associations; putative biological advantage. 
Curr Drug Targets Inflamm Allergy. 2005 Feb; 
4(1):105-112. 
8. Tekin M, Yalçinkaya F, Tümer N, Cakar N, Koçak H, 
Ozkaya N, Gençgönül H. Familial Mediterranean 
fever--renal involvement by diseases other than 
amyloid. Nephrol Dial Transplant. 1999 Feb;14(2):475-
479. 
9. Gedalia A. Familial Mediterranean fever. In: Behrman 
R, Kleigman R, editors. Nelson textbook of pediatrics. 
17th ed. Philadelphia: WB Saunders; 2004. P. 821.  
10.  Duppenthaler A.  [Recurrent febrile episodes--normal, 
periodic fever syndrome or immunodeficiency?]. Ther 
Umsch. 2006 Oct;63(10):667-671. German.  
11. Wickiser JE, Saulsbury FT. Henoch-Schönlein 
purpura in a child with hyperimmunoglobulinemia D 
and periodic fever syndrome. Pediatr Dermatol. 2005 
Mar-Apr;22(2):138-141. 
12. Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir 
B, Ozen S. Familial Mediterranean fever and 
glomerulonephritis and review of the literature. 
Rheumatol Int. 2004 Jan; 24(1):43-45. 
13. Fisher PW, Ho LT, Goldschmidt R, Semerdjian RJ, 
Rutecki GW. Familial Mediterranean fever, 
inflammation and nephrotic syndrome: fibrillary 
glomerulopathy and the M680I missense mutation. 
BMC Nephrol. 2003 Aug 11;4:6. 
14. Miller M. Vasculitis syndromes. In: Behrman R, 
Kleigman R, editors. Nelson textbook of pediatrics. 
17th ed. Philadelphia: WB Saunders; 2004. P. 826-828. 
15. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and 
significance of mutations in the familial Mediterranean 
fever gene in Henoch-Schönlein purpura. J Pediatr. 
2003 Nov;143(5):658-661. 
16. Ruellan A, Khatibi M, Staub T, Martin T, Storck D, 
Christmann D. [Rheumatoid purpura and intravenous 
immunoglobulins]. Rev Med Interne. 1997;18(9):727-729. 
17. Orbach H, Tishler M, Shoenfeld Y. Intravenous 
immunoglobulin and the kidney--a two-edged sword. 








Recurrent Henoch-Schönlein purpura in FMF  
352   Acta Medica Iranica, Vol. 46, No. 4 (2008)    
18. Aries PM, Hellmich B, Gross WL. Intravenous 
immunoglobulin therapy in vasculitis: speculation or 
evidence? Clin Rev Allergy Immunol. 2005 Dec; 
29(3):237-245. 
19. Coppo R. Henoch-Schonlein purpura. In: Avner E, 
Harmon W, editors. Pediatric nephrology. 5th ed. 
Philadelphia: Lippincott; 2004. P. 851-860.  
20. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar 
M, Philippon C, Deforges L, Terzidis H, Intrator L, 
André C, Adnot S, et al. Immunomodulation with low-
dose immunoglobulins for moderate IgA nephropathy and 
Henoch-Schönlein purpura. Preliminary results of a 
prospective uncontrolled trial. Nephron. 1995; 69(3): 
327-334.  
 
www.SID.ir
